Ahmed, M., Khalil, K., Eida, M., Salem, A. (2022). Effect of Fecal Microbiota Transplant versus Conventional Medications in Treatment of Irritable Bowel Syndrome. Afro-Egyptian Journal of Infectious and Endemic Diseases, 12(3), 218-230. doi: 10.21608/aeji.2022.136572.1223
Mona M Ahmed; Khalil A Khalil; Mohamed M Eida; Ayman Salem. "Effect of Fecal Microbiota Transplant versus Conventional Medications in Treatment of Irritable Bowel Syndrome". Afro-Egyptian Journal of Infectious and Endemic Diseases, 12, 3, 2022, 218-230. doi: 10.21608/aeji.2022.136572.1223
Ahmed, M., Khalil, K., Eida, M., Salem, A. (2022). 'Effect of Fecal Microbiota Transplant versus Conventional Medications in Treatment of Irritable Bowel Syndrome', Afro-Egyptian Journal of Infectious and Endemic Diseases, 12(3), pp. 218-230. doi: 10.21608/aeji.2022.136572.1223
Ahmed, M., Khalil, K., Eida, M., Salem, A. Effect of Fecal Microbiota Transplant versus Conventional Medications in Treatment of Irritable Bowel Syndrome. Afro-Egyptian Journal of Infectious and Endemic Diseases, 2022; 12(3): 218-230. doi: 10.21608/aeji.2022.136572.1223
Effect of Fecal Microbiota Transplant versus Conventional Medications in Treatment of Irritable Bowel Syndrome
1Department of Internal Medicine, Suez Canal University Hospitals, Faculty of Medicine, Suez Canal University, Ismailia, Egypt.
2Department of Endemic and Infectious Diseases, Faculty of Medicine, Suez Canal University, Ismailia, Egypt
Abstract
Background and study aim: Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder with 10%-15% prevalence. Altered intestinal microflora is common in IBS so the current study aims to figure out the effect of fecal microbiota transplant (FMT) on patients suffering from IBS. Patients and Methods: The study included 30 patients attended internal medicine clinic of the Suez Canal University Hospital, Ismailia, Egypt. All were inquired about IBS symptoms using Rome III criteria, patients classified into three groups: group A: healthy donors, group B: patients who received Mebeverine and Simethicone and group C: patients who managed by FMT. Patients were asked to register their symptoms using the IBS-severity scoring system (IBS- SSS) after 2 weeks and one month. The stool for FMT of the donors was prepared and introduced to patients via retention enema. Results: Significant improvement of quality of life (QoL) in group B was 47.74 ± 40.43% after 2 weeks and 26.14 ± 50.28% after one month. In group C, the improvement was 82.57 ± 20.94% after 2 weeks that became 79.57 ± 21.49% after one month. The pain score before treatment was 70 in group B and 75 in group C then after 2 weeks pain score was 35 in group B and 20 in group C and after one month pain score was 70 in group B and 20 in group C. Patients in both groups B and C have constipation that improved markedly in group C more than group B. Conclusion: FMT is a good method of treatment of IBS patients .
Highlights
FMT can change the gut microbiota in patients with IBS.
This study highlights the potential role of microbiota manipulations in IBS.
It also highlights the importance of the donor microbiota for treatment success.
A strategy to select appropriate donors and maximize donor-host microbiome compatibility for a beneficial treatment success still needs to be developed.
Irritable bowel syndrome (IBS) is defined as abdominal pain and discomfort with altered bowel habits in the absence of any other mechanical, inflammatory, or biochemical explanation for these symptoms [1]. IBS is a chronic condition that severely impacts the quality of life of affected individuals [2]. It is the most common functional digestive disorder. The prevalence of IBS is ranged between 10-20 % worldwide [3]. IBS is thought to have a complex etiology that involves changes in gastro-intestinal motility, small- bowel bacterial overgrowth, microscopic inflammation, and visceral hypersensitivity, according to recent study [4]. IBS has been linked to bacterial overgrowth in the small intestine. In patients with bacterial overgrowth, the main migratory complex is reduced [5].
Because there are no cures for IBS, treatment is palliative and supportive, focusing on individual symptoms, yet it is notoriously unsatisfactory [6]. Intestinal microbiota has been found to be altered in IBS patients, as well as an increase in symptoms following enteric infections, suggesting that restoring intestinal microflora may be a good therapeutic target [7,8]. Different treatment options for IBS include dietary manipulation, peppermint oil, antispasmodics, loperamide, antidepressants, psychological therapies including hypnotherapy, serotonergic agents, prosecretory agents, antibiotics; rifaximin and modifying the colonic microbiota: probiotics, prebiotics [9].
A fecal microbiota transplantation (FMT) is the transfer of fecal material containing bacteria and natural antibacterial from a healthy individual into a diseased recipient. These terminologies have been replaced by the new term faecal microbiota transplantation because the technique involves the total restoration of the entire faecal microbiota, not just a single agent or combination of agents [10]. FMT involves re-establishing healthy bacterial Flora in the colon by infusing faeces, e.g., by enema, orogastric tube, or orally in the form of a capsule containing freeze-dried material taken from a healthy donor [11]. Other gastrointestinal illnesses, such as colitis, constipation, and IBS, have been treated with FMT on experimental basis. [12]. Autoimmune disorders, obesity, metabolic syndrome and diabetes [13], and neurological conditions such as multiple sclerosis and Parkinson's disease can also modulated by FMT [14]. The current study aims to figure out the effect of fecal microbiota transplant and conventional medications among patient suffering from IBS.
PATIENTS AND METHODS
This is a comparative cross sectional study This clinical trial study was carried out at the internal medicine clinic of the Suez Canal University Hospital, Ismailia, Egypt. The study included 30 patients aging 19 - 60 years of both female and male gender who were inquired about IBS symptoms using Rome III criteria [15] and divided to 3 groups (A, B and C), 10 patients in each group.
Group A: (control group) healthy individual and they were the donors.
Group B: patients who suffer from IBS and received conventional medications.
Group C: patients who suffer from IBS and was managed by fecal microbiota transplant (FMT). All were selected by convenience sampling after approval and signing an informed consent. Participants responded to a short questionnaire including sociodemographic data. In the Suez Canal University Hospital's internal medicine clinic, IBS patients were diagnosed using the Rome III criteria after ruling out any other organic bowel disease. Rome III criteria: recurrent abdominal discomfort that occurs at least once a week on average during the previous three months and is associated with two or more of the following:
- Symptoms linked to defecation (increased or unaltered)
- Symptoms associated with a change in stool frequency;
- Symptoms associated with a change in stool form or appearance.
All patients were seen for study visits at baseline, 2 weeks and 1 month, where they completed the IBS-severity scoring system (IBS- SSS) and all the patients who didn’t commit with the 3 visits were excluded from the study. [16]
Conventional medications (commonly used drugs)[17]
Mebeverine 135 mg tab 3 times per day and Simethicone chewable tab 3 times per day.
Administration of Donor Material Donors
Three faecal donors were recruited in the study. All donors were screened according to standard guidelines for FMT donors [18], and were recruited according to criteria described in detail elsewhere [19]. In summary, the three donors were healthy adults aged between 18–45 years with no current medicine consumption. Furthermore, the donors were characterized by having normal bowel movements, defined as 1–2 bowel movements per day of type 3–4 on the Bristol Stool Form Scale (BSFS) [20].
Donor material
The evening before the fecal transplant, the donor takes a laxative at bedtime. On the morning of the procedure, the donor collects a fistful-sized amount of stool which equals approximately 200–300 grams of fecal material. The specimen was dissolved with saline then filtered by doubled gauze layer for particles. For transport, it was stored in a clean, plastic container, kept cool and it was transplanted within 6 to 8 hours [21].
Procedure of FMT
Patients underwent bowel lavage and 100–150 mL of the donor fecal suspension (corresponding to approximately 50 g stool) was transferred via a rectal enema. Participants were asked to lie on their left side for 30 minutes after the enema. After the transfers, patients were given 2 mg loperamide, an opoid-receptor agonist, for 3 days to reduce bowel movements [22].
Methods of data collection
All persons included in the study were submitted to the following scheme pre and post intervention:
1) Questionnaire
Data will be collected by structured interview. According to items:
Basic demographic data (age, sex,…….).
Stool test to screen for parasites or ova (eggs), protozoa as Entamoeba histolytica which is more common also cause diarrheal illness.
2) Abdominal ultrasound to assess the liver, gall bladder and kidney condition.
3) Blood tests for thyroid stimulating hormone (TSH), random blood sugar (RBS), alanine aminotransferase (ALT), aspartate aminotransferase (AST) and serum creatinine were done to exclude other cause which can explain the patient's symptoms.
Statistical analysis [23][24]
Data were fed to the computer and analyzed using IBM SPSS software package version 20.0. (Armonk, NY: IBM Corp). Qualitative data were described using number and percent. The Kolmogorov-Smirnov test was used to verify the normality of distribution Quantitative data were described using range (minimum and maximum), mean, standard deviation and median. Significance of the obtained results was judged at the 5% level.
RESULTS:
The study included 30 patients with IBS. Male to female ratio was 1:2, of which 21 patients were from Urban areas (table 1). When comparing the 3 groups according to body mass index most of (IBS patients) were obese (7 in group C and 4 in group B) and (2 only in group A) (table 1).
Most of the patients in group B were constipation predominate (7 patients) and the others were alternative (3 patients), while in group C most of them were alternative type (6 patients) and others are constipation predominate (table 2).
Effect of FMT
*Abdominal symptoms and quality of life
Abdominal symptoms as measured using IBS-SSS were significantly improved after 2 weeks and 1 month for both groups B and C, The improvement in IBSSSS in group B was 41.48 ± 30.04% after 2 weeks that became 15.74 ± 31.08% after 1 month with significance between both results and between results before treatment and results 2 weeks after, but there's no significance when compare results before treatment and one month after treatment (figure 1).
In more detail, after 2 weeks, there were clinical improvements in the pain score of 46.67 and 85.18 of the patients in group B and group C, respectively, and became 21.64 and 80.77 after one month (table 3). The improvement in the quality of life was 47.74 and 82.57 in group B and group C, respectively after 2 weeks while it became 26.14 and 79.57 after 1 month (figure 2).
* Post prandial abdominal pain
Before treatment there's 8 patients developed abdominal pain after eating Most and some of the time in group B and 9 patients in group C with highly significant differences between groups. After 2 weeks there's 2 patients in both groups (B and C) still have abdominal pain after eating without significance between groups. One month after treatment there's 5 patients in group B and 3 in group C had abdominal pain after eating without significance between groups (table 5).
*Bowel habits and flatulence
The studied population has a constipation-predominant which was markedly improved in group C more than group B, 50.37% and 21.14% respectively (table 4). Regarding flatulence, there’s improvement in group B and group C when compare each group with base line data but no intergroup significance, in more details; The median of the score is 80 before treatment in group B and 70 in group C, with non-significant difference but with significant difference if compare each group with control. After 2 weeks score decrease markedly in both groups to be 40 and 20 in group B and C respectively with non-significant difference, but with significant difference if compared each one with control group. One month after, score became 70 in group B and 25 in group C and also there's no statistically significant difference between them, but it shows significant difference if compared each one with control group (table 6).
Table (1): Comparison between the different studied groups according to demographic data.
Group A
(n= 10)
Group B
(n= 10)
Group C
(n= 10)
Test of sig.
p
No.
%
No.
%
No.
%
Sex
Male
7
70.0
1
10.0
2
20.0
c2-
8.469
0.025*
Female
3
30.0
9
90.0
8
80.0
Age (years)
Min. – Max.
18.0 – 65.0
33.0 – 60.0
33.0 – 59.0
F=1.486
0.244
Mean ± SD.
35.60 ± 13.72
41.0 ± 9.72
44.50 ± 11.10
Median
33.50
36.50
40.50
BMI (kg/m2)
Under (>18.5)
0
0.0
0
0.0
0
0.0
c2-
5.376
MCp=
0.252
Normal (18.5 – 24)
4
40.0
4
40.0
2
20.0
Over (25 – 29.9)
4
40.0
2
20.0
1
10.0
Obese (>30)
2
20.0
4
40.0
7
70.0
Min. – Max.
22.0 – 33.0
20.0 – 35.0
23.0 – 37.0
F=1.487
0.244
Mean ± SD.
27.0 ± 3.88
27.70 ± 5.85
30.54 ± 4.65
Median
26.85
28.50
32.15
Address
Urban
8
80.0
6
60.0
7
70.0
c2-
1.009
MCp=
0.877
Rural
2
20.0
4
40.0
3
30.0
Marital status
Married
7
70.0
3
30.0
6
60.0
c2-
7.906
MCp=
0.200
Single
3
30.0
3
30.0
1
10.0
Divorced
0
0.0
3
30.0
3
30.0
Widow
0
0.0
1
10.0
0
0.0
Habits
Non – smoking
7
70.0
8
80.0
8
80.0
c2-
0.511
MCp=
1.000
Smoking
3
30.0
2
20.0
2
20.0
c2, p: c2 and p values for Chi square test for comparing between the three groups
F,p: F and p values for ANOVA test
MCp: p value for Monte Carlo for Chi square test for comparing between the three groups
*: Statistically significant at p ≤ 0.05
Statistical significance was assessed by non-parametric Mann-Whitney test or Student t test (for fecal calprotectin); gender distribution was analyzed by a chi-square test.
IBS, irritable bowel syndrome patients; FMT, fecal microbiota transplantation; IBS-D, IBS with diarrhea; IBS-C, IBS with constipation.
Table (2): Comparison between the two studied groups according to IBS type.
IBS type
Group B
(n= 10)
Group C
(n= 10)
c2
FEp
No.
%
No.
%
Before treatment
Alternative
3
30.0
6
60.0
1.818
0.370
Diarrhea predominate
0
0.0
0
0.0
Constipation predominate
7
70.0
4
40.0
c2, p: c2 and p values for Chi square test for comparing between the two groups
FEp: p value for Fisher Exact for Chi square test for comparing between the two groups
*: Statistically significant at p ≤ 0.05
Table (3): Comparison between the different studied groups according to abdominal pain.
Abdominal pain
Group A
(n= 10)
Group B
(n= 10)
Group C
(n= 10)
c2
MCp
No.
%
No.
%
No.
%
Before treatment
Most of the time
0
0.0
8
80.0
9
90.0
29.700*
<0.001*
Some of the time
0
0.0
2
20.0
1
10.0
Little of the time
1
10.0
0
0.0
0
0.0
None of the time
9
90.0
0
0.0
0
0.0
2 weeks after treatment
Most of the time
0
0.0
1
10.0
2
20.0
12.609*
0.017*
Some of the time
0
0.0
3
30.0
0
0.0
Little of the time
2
20.0
5
50.0
4
40.0
None of the time
8
80.0
1
10.0
4
40.0
1 month after treatment
Most of the time
0
0.0
5
50.0
3
30.0
25.198*
<0.001*
Some of the time
0
0.0
2
20.0
0
0.0
Little of the time
0
0.0
3
30.0
5
50.0
None of the time
10
100.0
0
0.0
2
20.0
Pain score
H
p
Before treatment
21.246*
<0.001*
Min. – Max.
0.0 – 10.0
50.0 – 80.0
50.0 – 80.0
Mean ± SD.
1.0 ± 3.16
69.0 ± 11.01
73.0 ± 9.49
Median
0.0
70.0
75.0
Sig. between groups
p1<0.001*,p2<0.001*,p3=0.544
2 weeks after treatment
12.337*
0.002*
Min. – Max.
0.0 – 10.0
0.0 – 70.0
0.0 – 80.0
Mean ± SD.
2.0 ± 4.22
38.0 ± 24.86
24.0 ± 30.98
Median
0.0
35.0
20.0
Sig. between groups
p1<0.001*,p2=0.032*,p3=0.181
1 month after treatment
19.099*
<0.001*
Min. – Max.
0.0 – 0.0
20.0 – 80.0
0.0 – 80.0
Mean ± SD.
0.0 ± 0.0
60.0 ± 21.60
33.0 ± 33.35
Median
0.0
70.0
20.0
Sig. between groups
p1<0.001*,p2=0.004*,p3=0.146
*: Statistically significant at p ≤ 0.05
c2, p: c2 and p values for Chi square test for comparing between the three groups
MCp: p value for Monte Carlo for Chi square test for comparing between the three groups
Table (4): Comparison between the different studied groups according to bowel habits.
Diarrhea
Group A
(n= 10)
Group B
(n= 10)
Group C
(n= 10)
c2
MCp
No.
%
No.
%
No.
%
Before treatment
All the time
0
0.0
0
0.0
0
0.0
10.785*
0.011*
Most of the time
0
0.0
0
0.0
0
0.0
Some of the time
0
0.0
2
20.0
6
60.0
Little of the time
1
10.0
3
30.0
1
10.0
None of the time
9
90.0
5
50.0
3
30.0
2 weeks after treatment
All the time
0
0.0
0
0.0
0
0.0
5.670
0.136
Most of the time
0
0.0
0
0.0
0
0.0
Some of the time
0
0.0
1
10.0
1
10.0
Little of the time
1
10.0
3
10.0
5
50.0
None of the time
9
90.0
6
60.0
4
40.0
1 month after treatment
All the time
0
0.0
0
0.0
0
0.0
10.265*
0.019*
Most of the time
0
0.0
0
0.0
0
0.0
Some of the time
0
0.0
1
10.0
1
10.0
Little of the time
1
10.0
3
30.0
7
70.0
None of the time
9
90.0
6
60.0
2
20.0
Constipation
Before treatment
All the time
0
0.0
3
30.0
1
10.0
21.124*
<0.001*
Most of the time
0
0.0
3
30.0
3
30.0
Some of the time
1
10.0
3
30.0
6
60.0
Little of the time
4
40.0
1
10.0
0
0.0
None of the time
5
50.0
0
0.0
0
0.0
2 weeks after treatment
All the time
0
0.0
3
30.0
0
0.0
15.341*
0.009*
Most of the time
0
0.0
1
10.0
1
10.0
Some of the time
1
10.0
3
30.0
2
20.0
Little of the time
4
40.0
3
30.0
7
70.0
None of the time
5
50.0
0
0.0
0
0.0
1 month after treatment
All the time
0
0.0
3
30.0
0
0.0
17.730*
0.003*
Most of the time
0
0.0
4
40.0
3
30.0
Some of the time
1
10.0
1
10.0
1
10.0
Little of the time
4
40.0
2
20.0
6
60.0
None of the time
5
50.0
0
0.0
0
0.0
*: Statistically significant at p ≤ 0.05
H, p: H and p values for Kruskal Wallis test, Sig. between groups was done using Post Hoc Test (Dunn's multiple comparisons test)
p1: p value for comparing between control and Group B
p2: p value for f comparing between control and Group C
p3: p value for comparing between Group B and Group C
Table (5): Comparison between the different studied groups according to presence of pain after eating.
Pain after eating
Control
(n= 10)
Group B
(n= 10)
Group C
(n= 10)
c2
MCp
No.
%
No.
%
No.
%
Before treatment
All the time
0
0.0
0
0.0
0
0.0
20.443*
<0.001*
Most of the time
0
0.0
2
20.0
2
20.0
Some of the time
0
0.0
6
60.0
7
70.0
Little of the time
3
30.0
1
10.0
1
10.0
None of the time
7
70.0
1
10.0
0
0.0
2 weeks after treatment
All the time
0
0.0
0
0.0
0
0.0
4.579
0.344
Most of the time
0
0.0
0
0.0
0
0.0
Some of the time
0
0.0
2
20.0
2
20.0
Little of the time
4
40.0
6
60.0
5
50.0
None of the time
6
60.0
2
20.0
3
30.0
1 month after treatment
All the time
0
0.0
0
0.0
0
0.0
8.563
0.154
Most of the time
0
0.0
0
0.0
1
10.0
Some of the time
0
0.0
5
50.0
2
20.0
Little of the time
6
60.0
3
30.0
4
40.0
None of the time
4
40.0
2
20.0
3
30.0
c2, p: c2 and p values for Chi square test for comparing between the three groups
MCp: p value for Monte Carlo for Chi square test for comparing between the three groups
*: Statistically significant at p ≤ 0.05.
Table (6): Comparison between the different studied groups according to flatulence.
Flatulence
Group A
(n= 10)
Group B
(n= 10)
Group C
(n= 10)
c2
MCp
No.
%
No.
%
No.
%
Before treatment
All the time
0
0.0
2
20.0
1
10.0
28.670*
<0.001*
Most of the time
0
0.0
8
80.0
8
80.0
Some of the time
0
0.0
0
0.0
1
10.0
Little of the time
5
50.0
0
0.0
0
0.0
None of the time
5
50.0
0
0.0
0
0.0
2 weeks after treatment
All the time
0
0.0
0
0.0
0
0.0
8.734
0.151
Most of the time
0
0.0
2
20.0
1
10.0
Some of the time
0
0.0
3
30.0
2
20.0
Little of the time
4
40.0
4
40.0
5
50.0
None of the time
6
60.0
1
10.0
2
20.0
1 month after treatment
All the time
0
0.0
1
10.0
0
0.0
15.552*
0.007*
Most of the time
0
0.0
5
50.0
3
30.0
Some of the time
0
0.0
2
20.0
1
10.0
Little of the time
7
70.0
2
20.0
6
60.0
None of the time
3
30.0
0
0.0
0
0.0
Flatulence score
Before treatment
0.0
80.0
70.0
<0.001*
2 weeks after treatment
0.0
40.0
20.0
0.001*
1 month after treatment
20.0
70.0
25.0
<0.001*
c2, p: c2 and p values for Chi square test for comparing between the three groups
MCp: p value for Monte Carlo for Chi square test for comparing between the three groups
*: Statistically significant at p ≤ 0.05.
DISCUSSION
This study aimed to identify the effect of fecal microbiota transplant versus conventional medications among patient suffering from IBS. Current evidence suggests the microbiota of the GI tract plays a substantial role in the aetiology of IBS. This is supported by several factors: IBS symptoms appear after an infectious gastroenteritis, temporary discomfort improvement following antibiotic [25]. The favourable benefits of FMT on IBS- related symptoms were attributed by Holvoet et al [26] to changes in the microbiota. Furthermore, antibiotics that are taken orally and are poorly absorbed by the GI system cause a temporary reduction in symptoms [27].
The Findings of this study show that FMT is an effective treatment for IBS that improves both the symptoms and quality of life, about half of the patients experienced significant clinical improvements in abdominal symptoms and quality of life. In addition, results mirror findings of the treatment effect on gastro-intestinal complaints by the IBS-SSS [28].
Regarding abdominal pain; all the patients in IBS groups (B and C) experienced abdominal pain before treatment which markedly decreased after 2 weeks in both groups B and C and also after one month, this improvement which occurred after FMT was matched with many studies: Andrews et al found that FMT using fecal enema infusions, 89% of whom (40 of 45 patients) reported relief in abdominal pain immediately after the procedure [29].
Other study of 13 patients at Montefiore Medical Center in New York City who underwent FMT for refractory IBS after interventions of dietary modification, probiotics, antibiotics, and/or anti-depressants had failed (9 IBS-diarrheal, 3 IBS-constipated, 1 IBS-mixed), 70% of patients reported improvement or resolution of symptoms and decrease of abdominal pain 72% [30].
Mazzawi et al conducted a study with FMT in IBS-D patients [9 patients) according to the Rome III criteria in order to investigate the effect of FMT on symptoms and the density of duodenal enteroendocrine cells [31]. The IBS severity score and the IBS symptom questionnaire were completed before and 3 weeks after FMT. Abdominal pain scores were significantly reduced 3 weeks after FMT treatment (P = 0.005) [32].
In contrast of our study that shows significant relief in abdominal pain after mebeverine and simethicone treatment, a randomized trial, revealed that clinical improvement and relief of abdominal pain by mebeverine treatment were not statistically significant compared to placebo [33, 34].
There were no published studies about the effect of mebeverine and simethicone combination on the symptoms of IBS but there was meta-analysis found that by adding simethicone to mebeverine was more effective on relieving IBS symptoms more than mebeverine alone [32].
In our study, patients who had diarrhea, after FMT there was improvement which remains after one month from the procedure.
Regarding to the improvement through FMT our study was matched with Mazzawi et al whose investigated the effect of FMT on symptoms and the density of duodenal enteroendocrine cells in IBS- D patients. Nine patients were included according to the Rome III criteria published that there was improvement regarding diarrhea with P value (P = 0.0002) [34]. Lu et al was another study was matched with our study that showed a significant improvement in stool consistency after mebeverine treatment at 2 weeks (p < 0.01), with a significant reduction in daily defecation frequency (p < 0.05) [36].
Most of the patients in groups C improved markedly after 2 weeks and one month after FMT matched with Andrews et al whose published that 60% of patients had normal defecation, without laxative use which persisted 9 to 19 months later [29].
Also, Mazzawi et al conducted a study with FMT in IBS-D patients in 9 patients were included according to the Rome III criteria.
Constipation was significantly reduced 3 weeks after FMT treatment with p value (p = 0.02] [34].
In our study, in group B there was improvement of flatulence in 50% of the patients after 2 weeks and 70% in group C and no statistically significant difference between them, but it shows significant difference if compared with control group. This was nearly matched with Pinn et al as they treat 13 patients with refractory IBS with FMT through enema and reported that 70% of patients improved from Clatulence by 45% [38]. In 2015, Cruz Aguilar et al published an abstract about the treatment and results of 9 patients suffering from IBS (diagnosis depend on Rome III) treated with single FMT through a colonoscopy. Evaluation of the treatment was performed 3 months after FMT using a standardized questionnaire and clinical evaluation. A 50% reduction in bloating was reported by 16% of the participants. Reduction of symptoms lasted only 8 weeks after FMT before a gradual reinstatement of symptoms occurred [39].
In our study and all mentioned studies report improvement after FMT with different percentages which may be explained as the assessment methods were subjective (questionnaire) not objective and to approve these results objective measurement as PCR was needed to measure type and number of microbiota before and after FMT.
Poynard et al., a meta-analysis of 26 selected double-blind randomized trials vs. placebo not consistent with our study that aimed to assess the efficacy of smooth muscle relaxants (mebeverine) in the treatment of patients with irritable bowel syndrome, reported that no significant differences were observed for abdominal distension when using mebeverine as treatment for IBS [40].
A marked improvement in QoL in group B and C and after one month the improvement in group C was nearly as the same as after 2 weeks while in group B became nearly same as before treatment without significance between both and significance observed if compare each one with control group. This is also consistent with earlier reporting of IBS-related QoL [41]. Our findings back up prior research that suggests that in a subpopulation of IBS, depression is caused by the gut rather than the brain. In around half of the instances, IBS symptoms appear first, with psychological anguish appearing afterwards [42].
Furthermore, a 2017 randomized controlled research indicated that probiotics improved depression scores and altered brain activity in IBS patients [43].
Monnikes et al was another study that not consistent with our study and found in IBS patients who treated for 8 weeks with mebeverine, QoL score was significantly improved by 44% and the mean (p<0.001) [55], Another prospective observational cohort study showed that the treatment with mebeverine hydrochloride improved the QOL [44].
Improvement of IBSSSS in our patients is consistent with Hong et al who published an abstract on FMT treatment in 10 patients with moderate IBS that did not respond to traditional treatment. Patients answered the IBS severity score before as well as 1 and 3 months after FMT. Study outcomes included the length of symptom-free intervals, bloating, flatus, and abdominal pain, frequency of bowel movements, dyspepsia, and overall well-being before and after FMT. Eighty percent of the study participants experienced resolution or improvement of symptoms after FMT. Clinically significant improvements in IBS severity score were observed at only 1 month follow-up after FMT (132 ± 100) compared to baseline (252 ± 122) (p= 0.027). However, tend to return to their pre-treatment state within 3 months after FMT [45].
Syzenko et al published an abstract in 2016 on a study evaluating the effect of FMT in “treatment resistant” IBS patients. The results showed an abdominal pain resolution or significant improvement in 9 (75%) patients (p ≤ 0.01). Only 1 patient reported no change in pain level [35].
The main strength of this study is the complete characterization of participants at baseline and the further follow-up that allowed for novel discoveries about possible long-term effects of FMT treatment. There are some weaknesses in this study. We highlight a few of the most important: Although the safety profile is not evaluated in this study, however no major adverse events related to faecal matter in transplants have been documented in previous studies.
In Conclusion, using fecal microbiota transplant (FMT) as a method of treatment of IBS is an effective choice.
Conflict of interest: None.
Funding: None.
Ethical aspect:
The study was approved by the institutional ethical committee at Suez Canal University, Faculty of Medicine. The title, aim, and benefits of the study were explained individually to each participant and after approval, an informed consent was obtained from each participant.
References
1-Hertig VL, Cain KC, Jarrett ME, Burr RL, Heitkemper MM. Daily stress and gastrointestinal symptoms in women with irritable bowel syndrome. Nurs Res. 2007; 56:399– 406.
2-Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol. 2012; 10:712–721.e4.
3-Drossman DA, Camilleri M, Mayer EA, Whitehead WE. AGA technical review on irritable bowel syndrome. Gastroenterology 2002 Dec; 123[6]: 2108–2131.
4-Panagiotis K, Georgia L, Jannis K, George P, Irini O, Kostas M, et al. Prevalence, bowel habit subtypes and medical care-seeking behaviour of patients with irritable bowel syndrome in Northern Greece. Euro J Gastroenterology and Hepatology. 2009 Feb; 21[2]: 183-189
5-Vantrappen G, Janssens J, Hellemans J, Ghoos Y. The interdigestive motor complex of normal subjects and patients with bacterial overgrowth of the small intestine. J Clin Invest. 1977; 59:1158–1166.
6-Borody TJ, Paramsothy S, Agrawal G. Fecal microbiota transplantation: indications, methods, evidence, and future directions. Curr Gastroenterol Rep. 2013; 15:337.
7-Jeffery IB, O’Toole PW, Ou hman L, Claesson MJ, Deane J, Quigley EM, Simrén M. An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota. Gut. 2012; 61:997– 1006.
8- Kassinen A, Krogius-Kurikka L, Mäkivuokko H, Rinttilä T, Paulin L, Corander J et al. The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. Gastroenterology 2007 Jul;133(1):24-33.
9- Rebecca M Lovell and Alexander C. Irritable Bowel Syndrome in the Community: Systematic Review and Meta-Analysis. The American Journal of Gastroenterology 2012; 107, 991–1000.
11- Rowan, Karen [October 20, 2012]. "'Poop Transplants' May Combat Bacterial Infections". LiveScience.com. Retrieved October 20, 2012.
12- Borody, TJ; George, L; Andrews, P; Brandl, S; Noonan, S; Cole, P et al. "Bowel-flora alteration: a potential cure for inflammatory bowel disease and irritable bowel syndrome?". The Medical Journal of Australia 1989;150 (10): 604.
13- Brandt LJ, Borody TJ, Campbell J. Endoscopic fecal microbiota transplantation: "first-line" treatment for severe Clostridium difficile infection? J Clin Gastroenterol 2011; 45: 655-657.
14- Ananthaswamy, A. Faecal Transplant Eases Symptoms of Parkinson’s. New Scientis 2011; 209, 8-9.
15- Brian E. Lacy and Nihal K. Patel. Rome Criteria and a Diagnostic Approach to Irritable Bowel Syndrome, J Clin Med. 2017 Nov; 6(11) 99.
16- Francis CY, Morris J, Whorwell PJ. The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress. Aliment Pharmacol Ther. 1997; 11:395–402.
17- Susan K, Stephen M. Treatment of irritable bowel syndrome. Am Fam Physician. 2005 Dec 15; 72(12):2501-2508.
18- Stefano B , Carlo RS, Serena P, Enrico B, Gianluca I , Giovanni C et al:, Fecal Microbiota Transplantation: Screening and Selection to Choose the Optimal Donor. J Clin Med. 2020 Jun; 9(6): 175.
19- Halkjær SI, Christensen AH, Lo BZS, Browne PD, Günther S, Hansen LH, Petersen AM. Faecal microbiota transplantation alters gut microbiota in patients with irritable bowel syndrome: results from a randomised, double-blind placebo-controlled study. Gut. 2018 Dec;67(12):2107-2115.
20- Blake MR, Raker JM, Whelan K. Validity and reliability of the Bristol Stool Form Scale in healthy adults and patients with diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther. 2016;44(7):693– 703.
21- Elizabeth Perez , Christine H Lee, Elaine O Petrof. A Practical Method for Preparation of Fecal Microbiota Transplantation. Scand J Infect Dis 2016; 42:857–861.
22- Rebeca Cruz, Nina Wantia, Thomas Clavel, Maria Vehreschild, Thorsten Buch, Monther Bajbouj et al. An Open-Labeled Study on Fecal Microbiota Transfer in Irritable Bowel Syndrome Patients Reveals Improvement in Abdominal Pain Associated with the Relative Abundance of Akkermansia Muciniphila. Digestion 2019; 100:127–138.
23- Kotz S, Balakrishnan N, Read CB, Vidakovic B. Encyclopedia of statistical sciences. 2nd ed. Hoboken, N.J.: Wiley-Interscience; 2006.
24- Kirkpatrick LA, Feeney BC. A simple guide to IBM SPSS statistics for version 20.0. Student ed. Belmont, Calif.: Wadsworth, Cengage Learning; 2013.
25- Spiller R, Garsed K. Postinfectious irritable bowel syndrome. Gastroenterology. 2009; 136:1979–1988.
26- Holvoet T, Joossens M, Wang J, Boelens J, Verhasselt B, Laukens D, et al. Assessment of faecal microbial transfer in irritable bowel syndrome with severe bloating. Gut. 2017; 66:980–982.
27- Menees SB, Maneerattannaporn M, Kim HM, Chey WD. The efficacy and safety of rifaximin for the irritable bowel syndrome: a systematic review and meta-analysis. Am J Gastroenterol. 2012; 107:28–35; quiz 36.
28- Johnsen PH, Hilpeusch F, Cavanagh, Leikanger IS, Kolstad C, Valle PC, Christian PV et al. Faecal microbiota transplantation versus placebo for moderate-to-severe irritable bowel syndrome: a double-blind, randomized,placebo-controlled, parallel-group, single-centre trial. Lancet Gastroenterol Hepatol 2018; 3 (1):17–24.
29- Andrews P, Borody TJ, Shortis NP, Thompson S. Bacteriotherapy for chronic constipation—long term follow-up. Gastroenterology. 1995; 108[4] A563.
30- Al Murayshid Abdurrahman , AljuliCi MZ , Al-Turki Yousef Prevalence of Irritable Bowel Syndrome among Students in King Saud University , Riyadh , Saudi Arabia. World Family Medicine Journal: Incorporating the Middle East. Journal of Family Medicine 2011 ;(9) 5:17-20.
31- Fujiwara Y, Kubo M, Kohata Y, Machida H, Okazaki H, Yamagami H et al. Cigarette smoking and its association with overlapping gastroesophageal reflux disease, functional dyspepsia, or irritable bowel syndrome. Intern Med. 2011;50(21):2443-7.
32- Andrews P, Borody TJ, Shortis NP, Thompson S. Bacteriotherapy for chronic constipation—long term follow-up. Gastroenterology. 1995;108(4) A563.
33- Pinn DM, Aroniadis OC, Brandt LJ. Follow-up study of fecal microbiota transplantation (FMT) for the treatment of refractory irritable bowel syndrome (IBS)Presented at: American College of Gastroenterology Annual Meeting; San Diego, CA; October 11-16, 2013.
34- Mazzawi T, Lied G, El-Salhy M, Gilja O, Hatlebakk J, Hausken T. P1527 Effect of faecal microbiota transplantation on symptoms and duodenal enteroendocrine cells in patients with irritable bowel syndrome. Unit Eur Gastroenterol J. 2016; (Suppl 2):2 (Suppl 1).
35- Syzenko G, Budovska L, Puchkov K. P0397 Efficiency of FMT in cases of ‘Treatment-resistant’ IBS. Unit Eur Gastroenterol J. 2016; (Suppl 2):2 (Suppl 1).
36- Lu CL, Chen CY, Chang FJ. Efect of a calcium channel blocker and antispasmodic in diarrhoea-predominant irritable bowel syndrome. J Gastroenterol Hepatol. 2000; 15:925–930.
37- Andrews P, Barnes P, Borody T. Chronic constipation reversed by restoration of bowel flora - a case and a hypothesis. Eur J Gastroenterol Hepatol. 1992; 4:245–7.
38- Pinn DM, Aroniadis OC, Brandt LJ. Follow-up study of fecal microbiota transplantation (FMT) for the treatment of refractory irritable bowel syndrome (IBS) Presented at: American College of Gastroenterology Annual Meeting; San Diego, CA; October 11-16, 2013.
39- Cruz Aguilar R, Buch T, Bajbouj Fecal microbiota transplantation as a novel therapy for irritable bowel syndrome with predominant diarrhea. Neurogastroenterol Motil. 2015; 27(Suppl 2):110.
40- Poynard T, Naveau S, Mory B, Chaput JC. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther. 1994 Oct;8(5):499-510.
41- Cash BD, Pimentel M, Rao SSC, WeinstockL, Chang L, Heimanson Z, et al. Repeat treatment with rifaximin improves irritable bowel syndrome-related quality of life: a secondary analysis of a randomized, double-blind, placebo-controlled trial. Therap Adv Gastroenterol 2017; 10(9):689–99.
42- Ford AC, Lacy BE, Talley NJ. Irritable bowel syndrome. N Engl J Med 2017; 376(26):2566–78.
43- Pinto Sanchez MI, Hall GB, Ghajar K, Nardelli A, BolinoC, Lau JT, et al. Probiotic BiCidobacterium longum NCC 3001 reduces depression scores and alters brain activity: a pilot study in patients with irritable bowel syndrome. Gastroenterology 2017; 153(2):448–59e8.
44- Monnikes H, Hecker H, Heymann-Monnikes I, Wiedenmann B, Schumann C. Predictive factors for therapeutic success in irritable bowel syndrome (IBS)in primary care (prC). Z Gastroenterol. 2001; 39:714.
45- Hong J, Bang B, Shin Y, Kim H, Kwon K. OP257 Treatment of Irritable Bowel Syndrome with Fecal Microbiota Transplantation: A case series of 10 patients. Unit Eur Gastroenterol J. 2016; (Suppl 2):2 (Suppl 1).
View on SCiNiTO
Top